The research team, led by Chengchi Xia, Tianshu Rong, and Baoqing Wang of the Second Affiliated Hospital of Xuzhou Medical University, extracted mortality records from the United States Multiple Cause of Death database for adults aged 25 and older between 1999 and 2023. They identified cases in which the underlying cause of death involved both a malignant neoplasm, coded C00 through C97 in the International Classification of Diseases, Tenth Revision, and respiratory failure, captured by codes J96.0 for acute failure, J96.1 for chronic failure, and J96.9 for unspecified failure. This dual-coding approach means the analysis captures deaths in which cancer was the fundamental cause but respiratory failure was the immediate clinical event that precipitated the end of life.

The raw numbers are striking. Respiratory failure-associated deaths among adult cancer patients rose from 36,812 in 1999 to 79,968 in 2023, an increase of 117.23 percent. The age-adjusted mortality rate, standardized to the 2000 US population to account for demographic shifts, climbed from 20.78 per 100,000 in 1999 to 28.42 per 100,000 in 2023. Yet when the researchers fitted log-linear regression models across the entire period using Joinpoint regression software, the average annual percent change came out at negative 0.60 percent, a statistically significant long-term decline. The apparent contradiction between rising absolute deaths and a net downward rate reflects both population growth and the aging of the American population, which pushed more people into the highest-risk age brackets even as age-standardized rates improved for most of the period.

That improvement, however, was not smooth. Joinpoint analysis, which is designed to detect inflection points in mortality time series, revealed a synchronized reversal across all subgroups between 2018 and 2021. Among men, the annual percent change during that window was 5.02 percent, with a 95 percent confidence interval of 3.52 to 6.55. Among women it was 5.56 percent, with a confidence interval of 3.29 to 7.89. Before that inflection, male mortality had fallen at 2.15 percent annually from 1999 to 2014 and female mortality at 1.74 percent annually from 1999 to 2015. After 2021, both trends returned to statistical stability. The authors attribute this collective surge to a convergence of two forces: the COVID-19 pandemic, which hit immunosuppressed cancer patients with particular severity, and the cumulative pulmonary toxicity of modern oncological therapies.

The pathophysiology underlying this pattern is layered. Respiratory failure in cancer patients can arise through direct neoplastic mechanisms, such as tumor invasion of lung parenchyma, metastatic infiltration, or compressive airway obstruction, and through indirect systemic pathways including paraneoplastic syndromes, cancer-associated cachexia, and generalized frailty. Superimposed on these is treatment-related lung injury, which can be triggered by localized radiotherapy, cytotoxic chemotherapy, and newer targeted agents. Immune checkpoint inhibitors, which have transformed survival in melanoma, lung cancer, and many other malignancies, are also associated with immune-mediated pneumonitis that can progress to acute respiratory distress syndrome or interstitial pneumonia. As precision medicine extends survival, patients live longer with lungs that have accumulated damage from multiple pneumotoxic regimens, a phenomenon the authors describe as a survival paradox.

The pandemic amplified these vulnerabilities in ways the data make visible. Cancer patients, by virtue of immunosuppression from both their disease and its treatment, faced a lowered physiological threshold for SARS-CoV-2 infection to progress into acute respiratory failure. At the same time, the reallocation of intensive care resources and the deferral of routine oncological screening during 2020 and 2021 may have allowed cancers to be diagnosed at more advanced stages, increasing terminal complications. The surge in mortality between 2018 and 2021 was disproportionately concentrated in non-metropolitan areas and among minoritized populations, suggesting that the acute shock of COVID-19 did not create health disparities so much as it exposed and intensified long-standing structural ones.

Those disparities are among the study’s most consequential findings. In 2023, non-Hispanic Black individuals had an age-adjusted mortality rate of 34.56 per 100,000, well above the 29.13 rate for non-Hispanic White individuals, the 22.07 rate for Hispanic populations, and the 19.48 rate for the non-Hispanic Other category. The authors point to a higher prevalence of shared cardiopulmonary risk factors, including smoking, obesity, and chronic obstructive pulmonary disease, as one mechanism, and cite evidence suggesting heightened susceptibility to arterial stiffness and elevated peripheral resistance among Black Americans, which may reduce tolerance for treatment-related complications. Socioeconomic inequities and differential access to healthcare resources compound these biological and behavioral factors.

Geography tells a parallel story. State-level analysis revealed an extreme range in mortality, from 15.6 per 100,000 in Maine to 58.4 per 100,000 in Mississippi, meaning residents of the highest-burden states face a risk nearly 3.7 times greater than those in the lowest. The urban-rural divide proved especially durable: metropolitan areas saw a significant long-term decline in mortality, with an average annual percent change of negative 1.15 percent, while non-metropolitan areas remained essentially flat at negative 0.18 percent, a difference the authors describe as an entrenched divergence. By 2023, the non-metropolitan rate of 30.52 per 100,000 exceeded the metropolitan rate of 25.25. The researchers attribute this gap to a cascading failure in rural healthcare access, where chronic shortages of primary care physicians delay cancer screening and diagnosis, and where resource-constrained hospitals cannot provide the lung-protective ventilation strategies and non-invasive respiratory support available in urban tertiary centers.

Looking forward, the team constructed autoregressive integrated moving average models to project mortality trajectories through 2046. Under the assumption that prevailing trends continue, the overall age-adjusted rate is forecast to rise from 28.4 per 100,000 in 2023 to 42.4 in 2046, an increase of roughly 49.2 percent. Men are projected to reach 44.9 per 100,000, while women, despite starting from a lower baseline of 24.3, are projected to experience the largest percentage increase, reaching 38.8 per 100,000, a jump of 59.7 percent. The authors are careful to frame these projections as heuristic scenarios rather than definitive forecasts. The 95 percent confidence intervals are exceptionally wide, spanning from 14.9 to 75.0 per 100,000 for the male cohort, reflecting the inherent volatility of extrapolating from a period that includes a global pandemic.

The study has limitations the authors acknowledge candidly. Reliance on ICD-10 codes introduces diagnostic non-specificity, since respiratory failure is sometimes recorded as a terminal coding diagnosis that reflects the physiological dying process rather than a specific oncological complication. The absence of granular clinical data on cancer staging, respiratory failure severity, and specific treatment regimens prevents definitive causal attribution to any single pneumotoxic therapy. Unmeasured confounders such as individual socioeconomic status and screening intensity may also shape the observed patterns. Still, the central message is difficult to dismiss: as cancer care extends lives, the lungs of survivors are emerging as a critical battleground, and the researchers argue that institutionalizing collaboration between oncology and pulmonary medicine, along with targeted screening for high-risk populations, is essential to prevent the projected escalation from becoming reality.

Subject of Research: Mortality trends from respiratory failure among US adult cancer patients from 1999 to 2023

Article Title: Trends in cancer-and respiratory failure-related mortality in the US adult population: an analysis of the CDC WONDER database from 1999 to 2023

Article References: Xia, C., Rong, T., & Wang, B. (2026). Trends in cancer-and respiratory failure-related mortality in the US adult population: an analysis of the CDC WONDER database from 1999 to 2023. Frontiers in Cancer Control and Society, 4, Article 1752674. https://doi.org/10.3389/fcacs.2026.1752674

Image Credits: AI Generated

DOI: 10.3389/fcacs.2026.1752674

Keywords: respiratory failure, cancer mortality, CDC WONDER, health disparities, COVID-19, pulmonary toxicity, age-adjusted mortality rate, rural health, immune checkpoint inhibitors, joinpoint regression, ARIMA forecasting, cancer survivorship

Motor neuron disease encompasses a group of progressive disorders in which the nerve cells that control voluntary muscle movement degenerate and die. The most familiar form is amyotrophic lateral sclerosis, or ALS, but the category also includes other rarer variants. In the study, researchers identified deaths using the International Classification of Diseases, 10th Revision code G12.2 listed as the underlying cause of death. Over the 26-year study window, annual deaths rose from 5,121 in 1999 to 7,551 in 2024, a 47.45 percent increase. On its face, that trajectory might suggest an escalating epidemic. Yet when the researchers adjusted for the changing age structure of the population, a different picture emerged: the age-adjusted mortality rate actually declined slightly, from 2.87 to 2.58 deaths per 100,000 population.

The gap between raw counts and adjusted rates is one of the most instructive technical points in the analysis. Because the American population has aged considerably since 1999, with a rapidly expanding share of adults in the age brackets where motor neuron disease is most common, raw death counts naturally rise even if an individual’s underlying risk does not. Age-adjusted mortality rates correct for this demographic shift by applying observed age-specific death rates to a standard population, allowing like-for-like comparisons across time. The authors used joinpoint regression, a statistical technique that identifies points in time where trends change direction, to estimate annual percentage changes and average annual percentage changes. The result: an overall average annual percentage change of minus 0.50 percent, with a 95 percent confidence interval spanning from minus 1.24 to plus 0.24 percent, a range that includes zero and therefore indicates no statistically clear long-term increase or decrease.

Beneath that overall stability, however, the mortality burden was far from evenly distributed. Deaths were heavily concentrated among adults aged 65 years and older, among men, and among non-Hispanic White individuals. These demographic patterns are consistent with much of the prior epidemiological literature on motor neuron disease, which has repeatedly noted both older age at onset and a modest male predominance. For age-group analyses, the researchers used crude mortality rates specific to each age band, since age adjustment is unnecessary when comparing within a single age stratum. For all other stratifications, including sex, race and ethnicity, census region, state, and level of urbanization, the age-adjusted mortality rate served as the primary metric.

Geography told its own revealing story. The South recorded the largest total number of motor neuron disease deaths, a finding shaped partly by the sheer size of that region’s population. But when rates rather than counts were compared, it was the Midwest that carried the highest age-adjusted mortality rate. The distinction matters: total counts reflect population size, while rates reflect underlying risk after demographic correction. A parallel pattern emerged along the urban-rural divide. In analyses covering 1999 through 2020, the most recent period for which urbanization classifications were available, age-adjusted mortality rates were consistently higher in nonmetropolitan areas than in metropolitan ones. The authors stress, however, that these stratified and state-level results should be interpreted as descriptive and exploratory rather than as evidence of causal differences between places.

Why might rural areas show elevated rates? The study itself does not test explanations, but the rural-metropolitan gap aligns with plausible hypotheses that researchers have long considered, including differences in occupational exposures, environmental factors, healthcare access, and diagnostic patterns. Rural populations tend to be older on average, and access to neuromuscular specialists and advanced diagnostic resources is often thinner outside major metropolitan centers, factors that could influence both true disease occurrence and the likelihood that a death is correctly attributed to motor neuron disease on a death certificate. Death-certificate data, while invaluable for tracking long-term and geographic patterns, are inherently subject to coding practices that may vary across providers, regions, and eras.

The methodological architecture of the study is worth appreciating. CDC WONDER aggregates Underlying Cause of Death data from the National Center for Health Statistics, providing publicly available, anonymous, aggregate-level mortality records covering the entire United States. Because the data are de-identified and population-level, the analysis required no institutional review board approval and involved no contact with individual participants. Serial cross-sectional designs like this one examine the population at repeated time points, stitching together annual snapshots into a long-term trend line. The trade-off is that such designs capture mortality patterns but cannot follow individuals forward in time, which limits causal inference. The authors are explicit that their findings describe patterns, not mechanisms, and that the state-level and stratified results are exploratory.

The practical implications lean heavily toward planning and resource allocation. The authors conclude that even with stable age-adjusted rates, the needs associated with motor neuron disease-related medical care, respiratory support, rehabilitation management, and public health services are likely to keep growing as the population ages. Motor neuron disease is relentlessly progressive: as motor neurons die, patients lose the ability to walk, speak, swallow, and eventually breathe, making multidisciplinary care, ventilatory support, and rehabilitation central to management. A rising volume of cases, driven by demography rather than by any change in per-person risk, translates directly into rising demand for neurologists, pulmonologists, respiratory therapists, physical and occupational therapists, palliative care teams, and caregiver support networks, particularly in the regions and community types where the registered burden is heaviest.

The study also illustrates a broader lesson for how health statistics should be read in an aging society. Raw counts of deaths from age-related diseases will climb in nearly every developed country simply because more people are living into the risk window. Age-adjusted rates are the tool that separates real changes in risk from demographic arithmetic, and here they suggest that the United States has not experienced a clear long-term escalation in motor neuron disease mortality risk per person over the past quarter century. That is not a cause for complacency; the absolute and growing number of affected families, the concentrated burden among older adults, and the persistent geographic and demographic disparities all demand sustained attention. But it reframes the narrative: America’s motor neuron disease challenge is primarily a story of population aging and uneven distribution, not of a sharply worsening underlying toll.

For researchers, the analysis sets a benchmark against which future studies can be measured. The slightly declining point estimate, with confidence intervals that straddle zero, leaves open the possibility of small increases or small decreases that larger or more granular datasets might resolve. Continued surveillance will be needed to track whether the expansion of therapies for ALS, improvements in supportive and respiratory care, and lengthening survival times alter mortality patterns in the decades ahead, since better management can extend life and, paradoxically, reshape how deaths are counted and classified. For now, the study provides clinicians, policymakers, and public health planners with a rigorous, nationally representative map of where and among whom motor neuron disease deaths occur, and a clear signal that the systems built to care for these patients must scale with the demographics of the country rather than with the per-capita rate alone.

One nuance worth noting is that the underlying cause of death on a certificate may not capture the full contribution of motor neuron disease to a person’s decline. Because respiratory failure is the usual terminal event, some deaths in which the condition was a contributing factor may be coded to other causes, meaning the figures here likely represent a conservative floor rather than a ceiling of the true mortality burden. The restriction to a single ICD-10 code also means that deaths classified under related codes would fall outside the count, a limitation the authors implicitly acknowledge by framing their results around registered mortality.

The demographic concentration among non-Hispanic White individuals also invites careful reading. Such patterns can reflect a mix of true differences in disease occurrence, differences in age structure across racial and ethnic groups, and differences in diagnostic access and certification practices. Disentangling those threads requires data sources richer than aggregate death records, such as population-based disease registries that capture incidence, survival, and treatment exposure rather than death alone.

Finally, the flat age-adjusted trend should not be read as evidence that the disease itself is static. Advances in multidisciplinary care, nutritional support, and respiratory management have gradually altered the natural history of these conditions, and longer survival can shift where and when deaths are recorded. Continued monitoring, ideally complemented by registry-based and clinical data, will be essential to interpret how evolving care patterns reshape the mortality landscape described here.

Subject of Research: Long-term mortality trends and geographic disparities in motor neuron disease among US adults from 1999 to 2024

Article Title: Mortality trends and geographic disparities in motor neuron disease among US adults aged 25 years and older, 1999–2024: a serial cross-sectional study using CDC WONDER

Article References: Jiang, R., Zhu, Q., Jiang, Q., Zhao, T., & Zhou, J. (2026). Mortality trends and geographic disparities in motor neuron disease among US adults aged 25 years and older, 1999–2024: a serial cross-sectional study using CDC WONDER. BMC Public Health. https://doi.org/10.1186/s12889-026-29374-x

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29374-x

Keywords: motor neuron disease, amyotrophic lateral sclerosis, mortality trends, CDC WONDER, age-adjusted mortality rate, geographic disparities, BMC Public Health, joinpoint regression, rural health, neurodegenerative disease, population aging, public health